| 产品描述: | 产品介绍:RXDX-106 (CEP-40783)是一种有效的、选择性的TAM(TYRO3, AXL, MER)/Met (c-Met)抑制剂,在肽段磷酸化实验中具有较低的纳摩尔级别生化活性;在体外激酶结合试验中具有慢速的解离率(T1/2 >120 min) |
| 体内研究: |
CEP-40783 shows dose- and time-dependent inhibition of AXL phosphorylation using NCI-H1299 NSCL xenografts with 80% target inhibition at 0.3 mg/kg 6 h post dose and complete target inhibition to >90% inhibition at 1 mg/kg between 6-24 h, while a 10 mg/kg po dose resulted in complete AXL inhibition up to 48 h post dosing. In 3/5 (60%) of the tumor models, CEP-40783 shows in vivo efficacy, including tumor regressions, significantly superior to that achieved with an optimal regimen of paclitaxel. In 4/4 (100%) of the erlotinib-insensitive tumor models, CEP-40783 demonstrates significant efficacy (66 to 118% TGI) compared to the control group at the 30 mg/kg dose. Additionally, CEP-40783 in combination with erlotinib demonstrate superior anti-tumor efficacy compared to CEP-40783 and erlotinib single agents in the one erlotinib-sensitive model evaluated. CEP-40783 as a single agent and in combination with erlotinib are well tolerated. |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
1.699 ml |
8.495 ml |
16.989 ml |
| 5 mM |
0.34 ml |
1.699 ml |
3.398 ml |
| 10 mM |
0.17 ml |
0.849 ml |
1.699 ml |
| 50 mM |
0.034 ml |
0.17 ml |
0.34 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |